Highlights ALTEOGEN Inc.

Equities

A196170

KR7196170005

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-29 pm EDT			5-day change	1st Jan Change
180,000 ^KRW	-1.15%		-3.17%	+82.74%

2023	Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA	CI
2023	ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA	23-09-05	CI
ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
ALTEOGEN Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
ALTEOGEN Inc. Enters into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by its Hybrozyme Technology	23-01-02	CI
Alteogen Inc. Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients	21-03-08	CI
Alteogen Enters Into Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled by Its Hybrozyme™ Technology	21-01-07	CI
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme Technology to Enable Subcutaneous Administration of Biologic Products	20-06-24	CI
ALTEOGEN Inc. Presents the First-In-Human Data on Alt-P7, A Her2-Targeting Antibody-Drug Conjugate At ASCO 2020	20-05-29	CI
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of its Hybrozyme™ Technology to Enable Subcutaneous Administration of Biologic Products	19-12-02	CI
Alteogen Inc. Signs Licensing Agreement with Cristalia Produtos Quimicos Farmaceuticos Ltda	19-07-22	CI
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH	18-12-03	CI
Tranche Update on ALTEOGEN Inc.'s Equity Buyback Plan announced on December 12, 2016.	17-06-12	CI
ALTEOGEN Inc.’s Equity Buyback announced on December 12, 2016 has expired.	17-06-11	CI
Qilu Pharmaceutical Co Ltd Enters into License Agreement with Alteogen Inc	17-04-02	CI
Tranche Update on ALTEOGEN Inc.'s Equity Buyback Plan announced on December 12, 2016.	17-03-14	CI
ALTEOGEN Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	16-12-11	CI
ALTEOGEN Inc. authorizes a Buyback Plan.	16-12-11	CI
3SBio Inc. Enters into an Exclusive Licensing Deal with Alteogen Inc	15-10-11	CI
ALTEOGEN Inc. has completed an IPO in the amount of KRW 23.40 billion.	14-12-10	CI
ALTEOGEN Inc. has filed an IPO in the amount of KRW 27.00 billion.	14-09-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ALTEOGEN Inc.

Equities

A196170

KR7196170005

Highlights

Filters